Yusuke Nakamura to Cyclophosphamide
This is a "connection" page, showing publications Yusuke Nakamura has written about Cyclophosphamide.
Connection Strength
0.364
-
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
Score: 0.149
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.132
-
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009 Oct; 54(10):564-71.
Score: 0.083